Our short, quick and targeted approach mixes qualitative and quantitative analysis. By applying market data, history, science and quantitative methods; we synthesize metrics of pricing the RegMed universe. RMI incorporates market dynamics, answering crucial questions and generating actionable investment recommendations.
Understanding and knowing the answer as the release is issued requires a historical knowledge of sector pricing to more than “questimate” share perception and rebounds.
December 18, 2017
Biostage (BSTG): Ponzi or Pyramid scheme or a combination of both …?
December 7, 2017
Biostage (BSTG) de-listing determination
November 28, 2017
Cesca Therapeutics (KOOL) proposes 900 K share offering priced at $3.00
November 16, 2017
AxoGen (AXGN) Prices offering of 2 M share at $21.00
November 14, 2017
Regenerative Medicine Earnings Scorecard - Q3/2017 to date
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at firstname.lastname@example.org.
Editor and Publisher ... Henry McCusker enters his thirteenth (13th) year at RegMed Investors